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Methods: A novel dual-sensor guide wire (Doppler flow and pressure) was used in 12 
patients with a single de nova lesion to simultaneously measure distal coronary pressure 
(Pd) and flow velocity (v), as well as aortlc pressure (Pa) after an i.c. bolus of adenosine. 
At maximal hyperemia, SRv and MRv were calculated as (Pa - Pd) / v and Pd / v, 
respectively. The results were compared before treatment and after balloon dilatation, 
stenting and upsized stenting guided by intravascular ultrasound. The relative contribu- 
tion of the decrease in SRv to the gain in flow velocity after PCI was estimated using the 
pre-PCI value of MRv. 
Results: Hyperemic SRv decreased from 2.1i2.2 CRU pre-PCI (1 CRU = 1 mm Hg/cm/ 
set) to 0.21+0.21 CRU (p = 0.01) due to PCI. Hyperemic MRv changed from 2.5+1.3 
CRU to 1.5iO.32 CRU (p = 0.02) after PCI. Compared to the pre-PCI level, the cumula- 
tive increase in hyperemic flow velocity was 146*163 %. 66.4*61.6 %, and 22.6i112.7 
% after each respective PCI step. The average relative contribution of the reduction in 
SRv to this gain in flow velocity was 46.6*44.9%. Conclusion: Dilation of the epicardial 
coronary lesion by PCI results in a significant reduction in stenosis resistance and a 
marked decrease in hyperemic coronary microvascular resistance, which accounts for 
about half of the resulting gain in hypetemlc flow velocity. These data suggest that dila- 
tion of the epicardial stenosis has a marked effect on coronary perfusion also through the 
accessory reduction of microvascular resistance. 
1197-192 Influence of Diabetic Treatment Status on Survival After 
Successful Percutaneous Coronary Intervention 
Verahese Mathew. Robert L. Frye, Ryan Lennon, Gregory W. Barsness, David R. 
Holmes, Jr., Mayo Clinic, Rochester, MN 
Background: The influence of diabetic treatment status on long-term outcome after per- 
cutaneous coronary intervention (PCI) is unclear: previous reports suggest that insulin 
treatment is associated with worse long-term outcome compared to patients not requiring 
insulin. Whether this IS an independent effect of insulin treatment, or whether insulin is 
merely a marker of mole advanced atherosclerosis or other unknown variables is uncer- 
tain. 
Methods and Results: Patients with diabetes undergoing successful PCI from January I, 
1996, through June 30,2001, were divided into two groups based on whether or not they 
required insulin, excluding patients with shock or recent (< 7days) infarction. Cox propor- 
tional hazards models were utilized to estimate the association between diabetes treat- 
ment status and long-term survival. Eleven hundred and four eligible diabetic patients 
were identified and divided into those treated with insulin (418 patients) and those treated 
with either an oral agent or diet alone (666 patients). Insulin-treated pabents were less 
likely to be male, had more pr!or coronary revascularization. prior myocardial infarction, 
and congestive heart failure on presentation. Angiographic and procedural characteris- 
tics were comparable. Adjusting for differences in baseline characteristics, insulin treat- 
ment did not adversely effect long-term survival (odds ratio (OR) 1 .lO, 95% confidence 
intervals (Cl) 0.77-1.58). 
Conclusion: Among diabetic patients undergoing successful PCI, patients treated with 
insulin have worse long-term suwival. However, when adjusting for differences in base- 
line characteristics, insulin treatment was not independently associated with worse long- 
term survival, suggesting that the difference observed in the crude survival rates are due 
primarily to differences in demographic, clinical, and treatment characteristics. 
1197-193 Incidence, Management, and Outcomes of Coronary 
Perforation: An Analysis of 16,296 Patients 
James L. Orford Panayotis Fasseas, Carmelo J. Panetta, Ali E. Denktas, David R. 
Holmes, Peter B. Berger, Mayo Clinic, Rochester, MN 
Background: Coronary perforation is a feared complication of percutaneous coronary 
intervention (PCI). Methods and Results: We performed a retrospective analysis of 
16,296 patients (pts) in the Mayo Clinic PCI database (1990-2001) Identifying 95 pts with 
coronary perforation (0.56%, 95% Cl 0.46, 0.71). The incidence was highest with athero- 
ablative devices (laser, atherectomy) (1.16% 95% Cl 0.76, 1.64) compared with balloon 
angioplasty alone (0.42%. 95% Cl 0.29, 0.61) 01 coronary stenting (0.23%, 95% Cl 0.15, 
0.35; p<O.OOl). Management strategies included covered stents and cardiac surgery 
(table). Seven pts died (7.4%, 95% Cl 3.7, 14.5). Glycoprotein llbillla inhibitor use (n=33: 
34.7%) did not predict the incidence of tamponade (p=O.43) or death (p=O.64). Conclu- 
sions: Coronary perforation following laser and atherectomy is 2-4 times more common 
than after balloon angioplasty or stent placement, respectively; is associated with a sig- 
niflcant moltakty (7%), but usually does not require surgery or result in tamponade or 
death. 
Coronary Perforation According to Ellis Classification: Management and Clln~cal Outcames 
All Type I 
@=95) (W17) 
Treatment, n (%) 
Type II Type Ill Type lV 
(nG.9) (Il=lE) (n=2) 
Protamine 22 (23) 2 (12) 
Balloon inflation 63 (66) 9 (53) 
Covered stent 3 (3) 0 
Pericardiocentes 7 (7) 0 
is 
Surgery lO(11) 0 
Outcomes, n (%) 
6 (14) 11 (61) 1 (50) 
34 (59) 18 (100) t (50) 
0 3 (7) 0 
0 7 (39) 0 
5 (9) 5 (26) 0 
Tamponade 11 (12) 0 1 (2) 10 (56) 0 
Death 7 (7) f (6) 3 (5) 3(17) 0 
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1197-194 Clinical Outcome After Prehospital Thrombolysis 
Versus Percutaneous Coronary Intervention for ST 
Elevation Myocardial Infarction: Results of the START 
in Berlin Pilot Study 
Stefan Hoffmann, Richard Stern, lskander Atmowihardjo, Dietrich Andresen, Vivantes 
Klinikum am Urban, Berlin, Germany 
Purpose: Despite the accepted superiority of PCI over in hospital thrombolysis (TL), 
there are no data demonstrating a benefit for PCI when compared with prehospital (p)TL. 
Berlin has a well organized pTL program, prevwsly been proven as a feasible and safe 
approach for the treatment of AMI. START is a prospective, randomized study evaluating 
the clinical outcome after pTL compared with direct PCI. 
Methods: Patients (pts) with STEMI less than 6 hours, enrolled by MICU physicians, 
were randomly asigned to pTL with reteplase or PCI with stenting. Primary endpoint 
(CEP) is a composite of MACE during hospital stay (all-cause mortality or recurent Ml 01 
new/worsening CHF or disabling stroke. 
Results: From October 2000 to March 2002, 66 Pts were enrolled (44.pTL, 44.PCI). 
Median time delay from symptom onset (SO) to MICU arrival was 70 (45.125)min, from 
SO to first bolus of TL 85 (61.137)mln and from SO to first ballon 143 (1 IO-195)min. Pts. 
mean age was 60 (49-69) years, 78% were males and 5l%had an anterior Ml. There 
were no differences between the two groups regarding baseline characteristics. The CEP 
was similary for pTL and PCI (13,6% vs. 15.9%). One recurent Ml occured in the pTL 
group, one death and one stroke in the PCI group. Thje incidence of CHF was equally for 
both treatments (13,6%). The need for urgent PCI was significantly higher I” the pTL 
group (32% vs. 5%, p=O.OOl). 
Conclusion: PCI does not offer clinical benefit over TL, when the administratlon of th 
drug starts very early in the prehospital setting. HOwever, the 32% rate of urgent PCI 
after thrombolytic therapy should focus on the need of a complex management strategy 
for AMI patients (invasive centers). 
1197-l 95 Aqueous Oxygen Therapy for ST-Segment Elevation 
Myocardial Infarction: AMIHOT Trial Design and 
Preliminary Results 
Jack L. Martin, Simon Dixon, Shukri David, Catherine Pensyl, Barbara Lindsay, William 
O’Neill, Main Line Health System, Bryr. Mawr, PA, William Beaumont Hospital, Detroit, 
Ml 
Background: Although rapid coronary reperfusion in ST segment elevation myocardial 
infarctlon (STEMI) improves recovery of left ventricular function and reduces mortality, 
epicardial vessel patency does not insure full restoration of nutrient flow at the tissue 
level. Animal and Phase 1 human testing of the TherOx@ Aqueous Oxygen (AO) System 
(TherOx Inc., Irvine, California) suggests that 6ercutaneous coronary infusion of autolo- 
gous blood mixed with hyperoxemlc saline may help overcome the downstream barrier to 
oxygen delivery in ischemic zones and improve myocardial salvage following primary 
angioplasty and stenting for STEMI. 
Methods: A Phase 2 randomized trial in the US is designed to evaluate the efficacv of 
regional A0 therapy in STEMI. A sub selective catheter is positioned in the infarct artery 
which delivers A0 oeriusion for 90 minutes at 75 ml/minute. Baseline contrast echocar- 
diography performed following coronary stenting and before randomization to A0 ther- 
apy or control is repeated at 24 hours, and days 30 and 90. Resting SPECT myocardial 
perfusion scans are obtained day 14. Prespecified endpoints include regional wall motion 
scores, SPECT perfusion defects and ST segment resolution. 
Results: Twenty patients have been randomized. Nine of IO patients assigned to A0 
therapy completed the 90 minute Infusion wthout hemodynamic 01 electrophysiologic 
instability. One patient could not cooperate due to noncardiac factors and received only 
68 minutes of infusion. Repeat angiography following A0 therapy documented stability of 
the pertwon catheter and maintenance of TIMI 3 flow in all subjects. The majority of the 
planned 250 patients are anticipated to be enrolled by March 2003. 
Conclusion: Preliminary results suggest that regional hyperoxemic therapy appears to 
be safe and can be readily applied in institutions performing primary angioplasty for 
STEMI. Conclusions regarding the promise of this new mode of therapy to improve 
recovery of left ventricular function requires longer-term follow up. 
1197-196 Effect of a Novel Pharmacological Strategy to 
Counteract Shivering During Endovascular Cooling for 
Acute Myocardial Infarction 
Simon R. Dixon, Shannon K. Maydick, Michael W. Dae, John T. Fox, Daniel I. Sessler. 
William W. O’Neill, William Beaumont Hospital, Royal Oak, MI, University of California 
San Francisco, San Francisco, CA 
Background: Mild hypothermia significantly reduces infarct size in experimental models 
of acute myocardial infarction (AMI). However, hypothermia triggers shivering, which is 
metabolically stressful. increases blood pressure and head rate, and often prevents fur- 
ther core cooling. We examined the efficacy and safety of a combined pharmacological 
strategy to suppress shivering in awake patients during endovascular cooling. 
Methods: One hundred and thirteen patients with acute ST-segment elevation Ml (c6- 
hours from symptom-onset) underwent primary PCI with adjunctive cooling. Hypothermia 
was induced using the SetPointa Temperature Management System (Radiant Medical 
Inc.. Redwood City, CA) to a target core temperature of 33°C for 3 hours after repedu- 
sion. The SetPoint system uses an endovascular heat exchange catheter that is placed 
in the inferior vena cava via the femoral vein. Skin warming, oral buspirone and intrave- 
nous meperidine were used to suppress shivering. 
Results: Seventy-eight (69%) patients had no evidence of shivering during cooling at an 
average minimum core temperature of 33+1 0°C. The remaining 35 patients experienced 
mild episodic shivering. Twenty-seven patients (24%) required additional boluses of 
meperidine to achieve a minimum core temperature of 33+l.o”C; nine patients (6%) 
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required a small increase in core temperature to 33.6*0.15”C. Meperidine and buspirone 
did not cause respiratory depression or other complications. Patients with shivering were 
younger (54 * 10 years vs. 59 * 12 years. p=O.O4), and received a higher total bolus 
dose of meperidine than those without shivering (156 f 66mg vs. 120 f 66mg, p=O.Ol). 
Mean patient weight and body surface area were similar in bath groups and no other 
demographic, clinical or hemodynamlc predictors of shivering were identified. 
Conclusion: Our results indicate that combination treatment with surface warming, bus- 
pirone and meperidine is safe and effective in patients with AMI, and provides a novel 
method for counteracting thermoregulatory defenses to systemic hypothermia during 
endovascular cooling. 
SES to control bare stents (CS), 462 pts (44%) had single vessel LAD treatment. In this 
cohort, reference vessel size was 2.74mm and lesion length was 14.0 mm. 
Results: Clinical (@ 9 months) and angiographic (@ 8 months) outcomes were com- 
pared in the SES and CS LAD subgroups (see table). 
Conclusions: The SIRIUS LAD substudy indicates striking improvement after SES in all 
clinical and angiographic efficacy parameters compared with CS. These SES results are 
equivalent to those reported after LIMA surgery, and thus, SES should be considered the 
new standard of care for stngle vessel LAD therapy. 
Follow-up parameter 
TLR (“‘o) 
TVR (%) 
MACE (%) 
Res (%): in-stent 
Res (%). In-lesion 
SES (n=234) CS (n=228) p value 
5.4 21.2 <O.OOl 
7.6 23.0 <O.OOl 
8.8 22.9 <O.OOl 
2.0 41.6 <O.OOl 
10.1 41.6 <O.OOl 
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1198-178 Volumetric Analysis of In-Stem lntimal Hyperplasia in 
Diabetic Patients Treated With or Without Abciximab: 
Results of the DANTE Randomized Trial 
Aurea J. Chaves, Luiz Mattes, Alexandre A. Abizaid, Rodolfo Staico. Fausto Feres, 
Marinella Centernero, LUIZ F. Tanajura, Andrea S. Abizaid, Ana S&as. lbraim Pinto, 
Marco Costa, Arilson Radrigues, Angela Paes, Amanda Sousa, Jose Eduardo M. Sousa, 
lnstituto Dante Pazzanese de Cardiologia. Sao Paula, Brazil 
Background: EPISTENT data showed that diabetic patients treated with stentiabcix- 
imab had their target vessel revascularlzation (TVR) reduced by approximately 50% 
when compared to stenffplacebo. Whether this is a result of a lower angiographic rest- 
enosis rate remains a subject of debate. Objective: To determine if abciximab is associ- 
ated with a reduced in-stent neointimal hyperplasia (IH), measured by intravascular 
ultrasound (IVUS), in diabetic patients. Method: The DANTE trial enrolled 96 diabetic 
patients (96 lesions) who underwent elective MULTILINK stat implantation for a de nova 
lesion of a native coronary artery randomized to be treated with or without abciximab. 
They were scheduled to undergo a 6.month angiographic and IVUS evaluation. Sample 
size calculations showed that 44 stented lesions/arm would be required to show a 25% 
reduction I” IH. Results: 
StenffAbciximab (n=47) Stem (n=49) p 
Age. Y 
Female, % 
Insulin Treated, % 
56.9 f 9.8 
46.8 
19.1 
Lesion Length, mm 11.5 * 4.7 
Stented Segment, mm 18.1 e4.0 
Reference Diameter, mm 2.99 * 0.49 
MLD pre 0.95 * 0.46 
MLD post 2.77 * 0.39 
MLD fup 1.75 * 0.69 
Acute Gain, mm 1.81 * 0.42 
Late LOSS, mm 1.03 * 0.63 
250% Restenosis, % 17.8 
30.day MACE, % 0 
60.6 f 8.5 
55.1 
16.3 
11.0 * 3.5 
19.8 f 5.6 
2.89 * 0.47 
0.84 * 0.35 
2.72 f 0.42 
1.66 f 0.63 
1.88 * 0.47 
1.07 * 0.58 
22.9 
0 
0.375 
0.416 
0.717 
0.537 
0.106 
0.283 
0.187 
0.574 
0.388 
0.484 
0.736 
0.539 
6month MACE, % 10.6 
NR, % 8.5 
Neointimal Volume, mm3 53.6 * 28.5 
Volume Obstruction, % 41.3 * 21.0 
MACE: death, Ml @-3x CKMB) or TVR 
22.4 0.121 
16.3 0.274 
60.7 + 40.8 0.344 
40.5 * 18.3 0.853 
Conclusion: In our study, volumetric analysis obtained in the d-month IVUS evaluation, 
showed that the administration of abciximab at the time of coronary stent implantation, 
was not associated with a reduction of neointimal hyperplasia in diabetic patients. 
1198-l 79 Should Sirolimus-Eluting Stents Be the New Standard 
for Left Anterior Descending Therapy? A SIRIUS 
Substudy 
Jeffrev W. Moses Dean Kereiakes, David 0. Williams, John Douglas, Charles Lambert. 
Charles Simonton, Michael Cleman, Charles Davidson, Timothy Vellinga, Martin B. 
Leon, Cardiovascular Research Foundation, New York, NY 
Background: The universal adoption of stenting to treat single vessel LAD disease has 
been llmited by increased target vessel revascularization -20.30%. leading to the pro- 
posal of LIMA surgery as an alternative therapy. Importantly, the effects of sirolimus-elut- 
Ing stents (SES) on LAD restenosis (Res) is not well defined. 
Methods: Of the 1058 pts in the randomized double-blind SIRIUS trial, which compared 
TLR=target lesion revascularizatlon 
TVR=target vessel revascularization 
MACE = major adverse cardiac events (death, MI, and repeat revascularlzation) 
1198-180 Effects of Sirolimus-Eluting Stents in Diabetic Patients: 
Volumetric Intravascular Ultrasound Analysis From the 
SIRIUS Trial 
Junva Ako, Yoshihiro Morino, Yasuhiro Honda, Shinjo Sonoda, Mitsuyasu Terashima, Ali 
Hassan, Judith J. Jaeger, Charles A. Simonton, David K. Roberts, Michael W. Cleman, 
Martin B. Leon, Jeffrey W. Moses, Paul G. Yock, Peter J. Fitzgerald. the SIRIUS 
investigators, Stanford University, Stanford, CA, Lenox Hill Hospital, New York NY 
Background: Exaggerated intimal hyperplasia has been reported to contribute to 
increased restenosis after percutaneous coronary tnterventlons in diabetic patients. The 
effects of drug-eluting stents in diabetic patients have not been well investigated. 
Methods: IVUS data were obtained from SIRIUS, a prospective, randomized, multi- 
center trial comparing sirolimus-eluting Bx VELOCITY stents (SES) vs. bare metal Bx 
VELOCITY stems (BMS). Eight-month follow-up 3-D IVUS analysis was available in 95 
cases (BMS 44: SES 51). Mean lumen (LA), stent @A), and neointimal areas (NIA) were 
obtained by dividing each volume with stent length. Cross sectional narrowing (CSN) 
was calculated as NIA divided by SA. The variables were compared by stent types (SESI 
EMS), presence of diabetes, and their Interactions. 
Results: There were 25 diabetic patients (BMS 13: SES 12). BMS showed a trend of 
decreased LA in diabetic patients compared to non-diabetic patients (p=O.O8). SES sig- 
nificantly suppressed neointimal hyperplasia in both diabetic and non-diabetic patients. 
There was no significant interaction effect between stent types and diabetes, indicating 
that the extent of neointimal suppression by SES was not affected by the presence of 
diabetes. 
Conclusions: Volumetric IVUS results of the SIRIUS trial suggest that sirolimus-eluting 
stents can provide suppression of neointimal hyperplasia that is as substantital in dia- 
betic patients as in non-diabetic patients. 
Table (*p=O.O8 vs. DM(-). BMS) 
BMS (n=44) SES (n=51) p-value 
NIA (mm3lmm) DM(-) 2.5il.3 0.18iO.3 <0.0001 
DM(+) 2.4kl.2 0.01*0.13 
LA (mm3lmm) DM(-) 5.3kl.7 6.7e2.0 <0.001 
DM(+) 4.3il.7’ 6.221.8 
%CSN DM(-) 31.4k12.8 2.8+5.1 <0.0001 
DM(+) 36.1i16.8 1.7i2.1 
Minimum lumen area (mm2) DM(-) 3.2kl.3 5.ikl.8 <0.0001 
DM(+) 3.1+2.0 4.5*1.7 
1198-181 About the Use of the ACHIEVE Paclitaxel Eluting 
Stent in Treatment of Restenotic Lesions: A 
Subanalysis of the 30-Day Safety Data of DELIVER II 
Antonio L. Bartorelli, Eberhard Grube, Didier Blanchad. Anthony Genhlick. Carlos 
Macava. Sophie Henrv. ChrIstran Homsv. on behalf of the DELIVER II investiaators. 
Centro Cardiologico Monzino, Milano, Italy, GUIDANT Europe, Diegem, Belgium 
Background: Many interventional cardiologists believe that restenosls following angio- 
plasty or stating is the most significant and pressing problem in the field of cardiology 
today. Stenting of coronary arteries resulted in a reduction of restenosis to 15.30% fol- 
lowing treatment of de nova lessons. But when restenosis of a stent does occur, recur- 
rence of in-stent restenosis treated with repeat PTCA ranges from 30% to as high as 
80% for diffuse in-stent restenosis. The DELIVER II study is a 1500 patients prospective, 
non-randomized, multi-center evaluation of the ACHIEVETM paclitaxel eluting Coronary 
Stat System in the treatment of lesions with high risk of revascularization due to rest- 
enosis. Such lesions include Chronic Total and Sub-Total Occlusions &TO). lesions 
